IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

BOLDRINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 368
AS - Asia 66
NA - Nord America 15
Totale 449
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 277
IT - Italia 64
CN - Cina 26
SG - Singapore 20
US - Stati Uniti d'America 15
FI - Finlandia 7
IN - India 6
RU - Federazione Russa 6
SE - Svezia 5
HK - Hong Kong 4
ID - Indonesia 3
KR - Corea 3
FR - Francia 2
GB - Regno Unito 2
AT - Austria 1
CZ - Repubblica Ceca 1
ES - Italia 1
JP - Giappone 1
MY - Malesia 1
NO - Norvegia 1
PH - Filippine 1
PL - Polonia 1
TR - Turchia 1
Totale 449
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 274
Singapore 16
Rho 14
Milan 9
Rome 8
Naples 7
Lappeenranta 6
Hong Kong 4
Beijing 3
Bengaluru 3
Desio 3
Jakarta 3
Ashburn 2
Bologna 2
Ravenna 2
Santa Clara 2
Seregno 2
Shanghai 2
Ankara 1
Boardman 1
Brno 1
Caserta 1
Chongqing 1
Cleveland 1
Eitensheim 1
Fort Worth 1
Gainesville 1
Gwangjin-gu 1
Helsinki 1
Hyderabad 1
Incheon 1
Johor Bahru 1
Kilburn 1
Longiano 1
Madrid 1
Magenta 1
Motherwell 1
Munich 1
Nuremberg 1
Oslo 1
Pasig 1
Sassari 1
Sovico 1
Tianjin 1
Tokyo 1
Vienna 1
Washington 1
Xi'an 1
Yongin-si 1
Totale 393
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 150
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study 95
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives 80
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials 75
Biomarkers for antibody-drug conjugates in solid tumors 54
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow 12
Pembrolizumab and oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1) 3
null 3
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Totale 473
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.197
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202317 0 0 0 0 0 0 0 0 0 0 10 7
2023/2024276 11 5 6 15 15 16 37 28 14 36 45 48
2024/2025180 39 37 53 51 0 0 0 0 0 0 0 0
Totale 473